Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Treatment of Retinal Vein Occlusion (RVO) With Open-Label Anecortave Acetate (15mg.)

NCT00211354 is registered in ClinicalTrials.gov with Manhattan Eye, Ear & Throat Hospital as lead sponsor.

NCT NCT00211354
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00211354 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Treatment of Retinal Vein Occlusion (RVO) With Open-Label Anecortave Acetate (15mg.)
Lead sponsor
Manhattan Eye, Ear & Throat Hospital
Phase
Phase 2
Overall status
Withdrawn
Start date
March 31, 2002
Completion date
April 30, 2007
Enrollment
0 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

retinal vein occlusion